Oral Answers to Questions

Debate between George Freeman and Jo Churchill

Tuesday 15th December 2015 Commons Chamber

[Jo Churchill (Bury St Edmunds) (Con)]

Will the Minister update the House about life science clusters as a way to stimulate start-ups, excellence and growth in the sector? Does he have any plans to use devolution city deals for such clusters?

[George Freeman]

My hon. Friend makes an important point, and around the country—not just in Cambridge, Oxford, and London MedCity, but in the Northern Health Science Alliance and the Scottish belt—the UK life science industry is building clusters of excellence and growth for the benefit of our citizens. I am holding discussions with the Chancellor and the Department for Communities and Local Government about how the devolution package could drive and support greater development of those health clusters around the country.

Oral Answers to Questions

Debate between George Freeman and Jo Churchill

Tuesday 17th November 2015 Commons Chamber

[Jo Churchill (Bury St Edmunds) (Con)]

7. What progress has been made by Genomics England in making the UK the world leader in genomic medicine.

[The Parliamentary Under-Secretary of State for Life Sciences (George Freeman)]

The Genomics England project, which was launched by my right hon. Friend the Prime Minister, has electrified the global life and health science community. We are the first nation on earth to commit to sequencing 100,000 entire genomes of NHS patients, which will be combined with patient records to unlock NHS and UK leadership in the fast-emerging field of genomic medicine, focusing initially on rare diseases and cancer. I am delighted to report that we have the genomes of 5,000 patients fully sequenced and that 11 genomic medicine centres have been set up. We have identified first diagnostics and treatments for some rare diseases; 2,500 researchers are involved in the project; the cost of sequencing a genome has fallen from £5,000 to £1,000; and, importantly, NHS England is setting the international standard on ethics and patient consent in genomic medicine.

[Jo Churchill]

Does the Minister agree that the world-leading Genomics England will deliver a personalised and patient-centred revolution in modern healthcare by combining the talent of global companies such as AstraZeneca with that of UK-based companies such as Congenica in my region, to the benefit of patients with cancer and other rare diseases, the vitality of our NHS and, through jobs and innovation, the strength of our economy?

[George Freeman]

My hon. Friend makes a great point. I pay tribute to Congenica, a small company in Cambridge that is doing extraordinary work. I recently went to open Illumina’s global research and development headquarters, which is a £160-million commitment. As well as the significant investment in technology and research in the UK, NHS England is leading genomic medicine across the UK, not just in the Oxford-Cambridge-London triangle, but through 11 genomic medicine centres across the country, which are bringing genomic diagnostics to the benefit of us all.

Oral Answers to Questions

Debate between George Freeman and Jo Churchill

Tuesday 10th November 2015 Commons Chamber

[Jo Churchill (Bury St Edmunds) (Con)]

What steps will the Minister take to promote reform of the EU regulations specifically on biotechnology and life science?

[The Parliamentary Under-Secretary of State for Life Sciences (George Freeman)]

My hon. Friend raises an excellent point. I was yesterday in Brussels with my right hon. Friend the Secretary of State to convene a summit with European leaders on biosciences. We are pushing for an enlightened regulatory framework to support EU and UK leadership in the fields of food, medicine and energy for global benefit.